Some People Not Appropriately Treated for High Cholesterol
Some HIV-positive people at high risk for heart disease are not having their levels of “bad” LDL cholesterol managed as aggressively as treatment guidelines recommend, say the authors of a single-clinic study published in the April 15 issue of Clinical Infectious Diseases.
The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III) sets cholesterol management guidelines, based on published research, to reduce people’s risk of developing heart disease. Guidelines recommend that if a person has high LDL levels, for example, they should first make dietary and exercise changes. If after 12 weeks of lifestyle modifications LDL is not reduced to target levels, medication is recommended to bring LDL to within the desired range.
James Willig, MD, and his colleagues from the University of Alabama at Birmingham (UAB) studied the medical records of people living with HIV who had their LDL cholesterol checked between July 2004 and December 2005 at the UAB clinic. To meet the criteria for analysis, the patients had to have their LDL cholesterol checked at three time points, with their first and second test results showing levels higher than those recommended in the NCEP-ATP III guidelines. Ninety patients met these criteria.
Willig’s team found that 44 percent were not prescribed medications—such as a cholesterol-lowering statin (e.g., Pravachol)—after failing to get their LDL to within the target range after 12 weeks of lifestyle modifications. What’s more, people with other heart disease risk factors, such as family history or smoking, were the least likely to be prescribed medications on top of their recommended lifestyle modifications. People whose other lipid levels, such as triglycerides, were too high, were the most likely to receive treatment intensification.
The authors comment that the percentage of people who did not receive optimal treatment in this study, a dynamic known as “clinical inertia,” is similar to the percentage found in HIV-negative patients. Clinical inertia may have one or several causes, including patient factors like non-adherence or poor health literacy, and physician characteristics such as lack of awareness of treatment guidelines. Willig’s team recommends that further studies should seek to determine which factors contribute most to clinical inertia in treating people with HIV who have high LDL levels.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Previous Comments:
comments 1 - 1 (of 1 total)
Ken Howard, West Hollywood, 2008-04-02 13:07:34
I agree that one should treat hyperlipidemia aggressively. I'm having to have hip replacement surgery due to Avascular Necrosis (bone death) of the head of my left femur (leg bone), and its cause very likely was the lack of blood supply to the head of the bone due to high trig levels that were only slightly treated and were "tolerated" years ago before I finally went on Lipitor and Zetia in recent years. To avoid AVN later, treat high lipids aggressively, NOW!
Beth Benne, RN, is HIV negative, but
the virus has impacted her life. She currently supervises a biannual HIV/AIDS awareness week as
the director of the student health center at Pierce College, a
community commuter school in Woodland Hills, California.
Woman of the Month is supported by exclusive advertising from Gilead.
Overheard in the Women's Forum
"I recently met a guy who is negative. I did tell him about my status and he decided to kiss me anyway (we didn't go further than that). But a day later, he called and said that he actually had a mouth ulcer that time when we kissed and he was very worried. Asked if he can get the virus from me that way. For that moment, I felt so insulted and yet I felt so bad. It was my first time having a contact with a "negative" guy."
